FDA Semaglutide Decision Signals Tougher Peptide Compounding Standard

On April 30, the U.S. Food and Drug Administration proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. FDA Source The action, paired with the prior resolution of GLP-1 drug shortages, effectively closes the legal pathway for industrial-scale compounded GLP-1s — a market that at its peak accounted for roughly 30 percent of U.S. supply. For the peptide compounding sector racing toward the July PCAC meeting, the decision is a preview of the regulatory logic that will govern their own pathway.

​

The Clinical Need Standard

The legal architecture matters here. Under Section 503B of the FD&C Act, outsourcing facilities may compound from a bulk drug substance only if that substance appears on the 503B Bulks List or if the compounded drug is on the FDA’s drug shortage list. Neither condition currently applies to semaglutide or tirzepatide — the shortages were declared resolved in early 2025 — so the April 30 proposal merely formalizes what the statute already requires.

“After evaluating the nominations for these three substances, the FDA did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances,” Commissioner Marty Makary said in the press announcement.

What counts as clinical need is the standard the industry should be watching. The FDA determined that the availability of FDA-approved GLP-1 products — Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound — eliminates the basis for bulk compounding absent a documented shortage. The same logic will apply to peptides. When FDA-approved drug products exist for the conditions peptides are used to address — and none of the 12 reclassified peptides have FDA approval for any indication — the clinical need determination will rest on different grounds. But the analytical framework is identical.

​

What This Means for the July PCAC Meeting

The Pharmacy Compounding Advisory Committee will meet July 23-24 to recommend whether seven of the 12 reclassified peptides — BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon — should be added to the 503A Bulks List. The April 30 decision is not directly binding on that process — PCAC operates under Section 503A, not 503B — but it establishes the enforcement posture.

“FDA has been unambiguous on this point in the GLP-1 context — issuing over eighty Warning Letters to telehealth companies for allegedly misleading marketing of compounded GLP-1 products in the twelve months ending March 2026,” FDA Law Blog noted. “There is every reason to expect the Agency to apply the same or similar framework to peptide marketing and promotion.”

The Partnership for Safe Medicines, a patient safety advocacy group, applauded the FDA action, citing hundreds of adverse events including sepsis, liver injury, and hospitalizations as well as recalls involving thousands of contaminated vials linked to mass-compounded GLP-1s. Safety advocacy groups are likely to submit the same arguments when the peptide docket opens for public comment.

​

The Supply Chain Gap

A separate challenge surfaced by multiple industry observers is supply chain readiness. Even if PCAC recommends 503A Bulks List placement in July, bulk API for peptide compounding must come from FDA-registered manufacturing establishments with certificates of analysis.

“Even if FDA acted tomorrow, pharmacies would still have to turn away those prescriptions because they couldn’t acquire the compliant API to prepare the drugs,” Scott Brunner, CEO of the Alliance for Pharmacy Compounding, told FDA Law Blog.

The April 30 decision reinforces the broader direction: FDA is narrowing, not expanding, bulk compounding pathways. The GLP-1 outcome shows how quickly a market built on regulatory ambiguity can contract when the legal basis for compounding is removed. Peptides currently occupy a more permissive posture — the Category 2 removal on April 15 was a genuine opening — but the enforcement architecture that governs what happens next is already being tested in real time.

​

What to Watch

The public comment period on the GLP-1 proposal closes June 29, 2026. Comments can be submitted through the Federal Register docket. Separately, the PCAC peptide docket accepts written comments through July 9, 2026 via Docket FDA-2025-N-6895.

Legislative action is also in play. The SAFE Drugs Act (S.3794), introduced in February by Senators Banks and Heinrich, would impose a 20-per-month cap on compounding of copies and require biennial inspections for large-scale outsourcing facilities. If enacted, it would add a statutory layer on top of the FDA’s enforcement framework.

For the full landscape on what the July PCAC meeting is expected to decide, see our PCAC meeting preview. See also our industry update on compounding pharmacy enforcement intensifying ahead of PCAC. For the supply chain and state-level variance that will affect access, see state variation in peptide access.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.